EGFR and non-small cell lung carcinoma: This study assessed the efficacy of osimertinib in comparison to standard chemotherapy in patients with resected stage IB-IIIA NSCLC (according to the eighth edition of TNM) and a verified EGFR-activating mutation (exon 19 deletion or exon 21 L858R).